SCHULMAN AMY W 4
4 · ALNYLAM PHARMACEUTICALS, INC. · Filed May 31, 2024
Insider Transaction Report
Form 4
SCHULMAN AMY W
Director
Transactions
- Exercise/Conversion
Common Stock
[F1]2024-05-29$66.83/sh+30,000$2,004,900→ 30,136 total - Sale
Common Stock
[F1][F2]2024-05-29$148.21/sh−10,121$1,500,033→ 20,015 total - Sale
Common Stock
[F1][F3]2024-05-29$148.93/sh−11,516$1,715,078→ 8,499 total - Sale
Common Stock
[F1]2024-05-29$149.76/sh−63$9,435→ 8,436 total - Exercise/Conversion
Stock Option (right to buy)
[F1][F4]2024-05-29−30,000→ 0 totalExercise: $66.83Exp: 2024-07-01→ Common Stock (30,000 underlying)
Footnotes (4)
- [F1]Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on February 28, 2024. The 30,000 options exercised by the reporting person were due to expire on July 1, 2024.
- [F2]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $147.62 to $148.60. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $148.63 to $149.52. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F4]This stock option was fully vested and exercisable as of July 1, 2017.
Signature
By: Brett Budzinski, Attorney-in-Fact For: Amy Schulman|2024-05-31